| HOME >> MEDICINE >> TECHNOLOGY |
9.1 Acute Lymphocytic Leukemia 342
9.2 Acute Myelogenous Leukemia 343
9.3 Anal Dysplasia 344
9.4 B-cell Lymphoma 344
9.5 Bladder Cancer 345
9.6 Bone Cancer 346
9.7 Brain Cancer 346
9.8 Breast Cancer 347
9.9 Cancer (general) 349
9.10 Cervical Cancer 350
9.11 Chemotherapy-induced Bone Marrow Injury (general) 351
9.12 Cervical Dysplasia 352
9.13 Chronic Myelogenous Leukemia 353
9.14 Colorectal Cancer 354
9.15 Gastrointestinal Cancer (general) 356
9.16 Gastrointestinal Stomach Cancer 356
9.17 Head and Neck Cancer 357
9.18 Hematological Cancer (general) 358
9.19 Leukemia (general) 358
9.20 Liver Cancer 359
9.21 Lung Cancer (general) 360
9.22 Lymphoma (general) 361
9.23 Melanoma 362
9.24 Mesothelioma 364
9.25 Myelodysplastic Syndrome 364
9.26 Myeloma 365
9.27 non-Hodgkin's Lymphoma 366
9.28 Non-Small Cell Lung Cancer 367
9.29 Oesophageal Cancer 369
9.30 Osteo Sarcoma 370
9.31 Ovarian Cancer 371
9.32 Pancreatic Cancer 374
9.33 Prostate Cancer 376
9.34 Renal Cancer 379
9.35 Skin Cancer (general) 381
9.36 Small Cell Lung Cancer 381
9.37 Soft Tissue Sarcoma 381
9.38 Solid Tumor 381
9.39 Squamous Cell Cancer 382
9.40 Thyroid Cancer 382
9.41 Unspecified Cancer Indication 383
9.42 Vaccine adjunct 386
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator 387
10.1 Competitive Fall-Out Assessment 387
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 389
10.3 AC Immune 390
10.4 Adaptimmune 392
10.5 Aduro BioTech 395
10.6 Advaxis 397
10.7 Aida Pharmaceuticals 402
10.8 Akela Pharma 404
'/>"/>| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |